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Objective: We aimed to identify prognostic factors of early-stage cervical adenocarcinoma (AC) and
adenosquamous carcinoma (ASC) treated with primary radical surgery, and to evaluate the impact of
postoperative adjuvant therapy on outcome.
Methods: The clinical-pathological data of all patients (n ¼ 1132) with stages I-II cervical AC/ASC treated
with primary radical surgery at the member hospitals of the Taiwanese Gynecologic Oncology Group
were retrospectively reviewed.
Results: In multivariate analysis, stage II, deep stromal invasion (DSI), lymphovascular space invasion
(LVSI), positive pelvic lymph node (PLN), and parametrial involvement (PI) were signiﬁcant factors for
recurrence-free survival (RFS), while only DSI, PI, and positive PLN were independent factors for cancer-
speciﬁc survival (CSS). Low- and high-risk groups were deﬁned by prognostic scores derived from the
four factors (DSI, LVSI, positive PLN, PI) selected by internal validation. Postoperative adjuvant therapy
signiﬁcantly improved outcome for PLN-positive patients (RFS, p ¼ 0.014; CSS, p ¼ 0.016), but not forrch Center, Chang Gung Me-
, Taiwan.
).
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
N.-F. Twu et al. / Surgical Oncology 25 (2016) 229e235230PLN-negative high-risk group because of higher mean prognostic score (p ¼ 0.028) of adjuvantþ than
adjuvant patients.
Conclusions: PLN metastasis, PI, DSI, and LVSI were independent prognostic factors. Prospective studies
of postoperative adjuvant therapy with prognostic score and nodal status stratiﬁcation for cervical AC/
ASC are necessary.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Cervical cancer is the thirdmost common cancer in female, with
estimated 528,000 new cases and 266,000 deaths in 2012 [1]. Most
cases are squamous cell carcinoma (SCC) histology. Less common
types include adenocarcinoma (AC), adenosquamous carcinoma
(ASC) (generally considered together), and other rare types [2].
Currently, ACs and ASCs (AC/ASCs) are treated similar to SCC [2,3],
though there is increasing evidence suggesting that AC/ASCs
behave differently from SCCs [2]. Equal cure rates may be obtained
with primary radiation therapy or radical hysterectomy with pelvic
lymphadenectomy (RH-PLND) for early-stage cervical cancer [4].
For avoiding the chronic radiation injury, removing the primary
tumor, and accurate surgical staging, primary radical surgery for
early-stage cervical cancer is preferred, particular in AC [5].
Following RH-PLND, adjuvant therapy is indicated for patients with
adverse pathological factors. Several pathological ﬁndings such as
pelvic lymph node (LN) metastasis, parametrial involvement (PI),
and deep stromal invasion (DSI) have been identiﬁed as risk factors
for recurrence [6,7].
For high-risk patients, the hazard ratios (HRs) for progression-
free and overall survival (PFS and OS) of postoperative adjuvant
radiotherapy versus chemoradiotherapy were 2.01 (p ¼ 0.003) and
1.96 (p ¼ 0.007), respectively [8], while adjuvant therapy may
reduce recurrence (HR 0.54 95% conﬁdence interval [CI] 0.35e0.81)
but may not signiﬁcantly improve survival (HR 0.70 95%CI
0.45e1.05) in the LN-negative patients with other poor prognostic
factors [9].
Compared to the marked decrease in the incidence of cervical
SCC, the incidence of cervical AC/ASC is increasing [10]. Cervical AC/
ASC and SCC could be different in prognostic factors and treatment
modality [11,12], but most of our knowledge on the studies of
prognostic factors and adjuvant therapy for early-stage cervicalcancer after primary surgical treatment comes from the patients
with SCC [11,12].
We aimed to conduct a multicenter retrospective study to
identify the prognostic factors of early-stage cervical AC/ASC
treated with RH-PLND, and to evaluate the impact of postoperative
adjuvant therapy on survival.
2. Materials and methods
2.1. Study population
All women with a diagnosis of International Federation of Gy-
necology and Obstetrics (FIGO) stages I-II cervical AC/ASC who
received RH-PLND as a primary treatment at the member hospitals
of the Taiwanese Gynecologic Oncology Group (TGOG) from
January 1991 through December 2011 were included in this study.
The study protocol was approved by the institutional review board
of each hospital. Medical records were retrospectively reviewed to
obtain patient’s demographics, surgical-pathologic data, and clin-
ical outcome. All patients were clinically staged using the FIGO
2009 staging system for cervical cancer [13]. Exclusion criteria
included histological subtypes other than AC or ASC, greater than
FIGO stages I-II, without primary surgical treatment, patients with
endometrioid adenocarcinoma from the uterine corpus.
2.2. Surgical-pathologic characteristics and adjuvant therapy
The pathologic slides were presented at the multidisciplinary
gynecologic oncology tumor board in each hospital. Tumors cate-
gorized as ASC showed both invasive AC and SCC elements. Adju-
vant therapy was given at discretion of the responsible physician,
most of the plans were discussed in a multidisciplinary conference.
In general, it was prescribed for the following indications: positive
Table 1
Patient’s characteristics (n ¼ 1132).
N (%)
Age (years)
45 510 (45.1)
>45 622 (54.9)
FIGO stage
I 984 (86.9)
II 145 (12.8)
N.-F. Twu et al. / Surgical Oncology 25 (2016) 229e235 231pelvic LN, PI, positive and/or close parametrial or vaginal margins,
and DSI (>50%) or large tumor size (>4 cm) with LVSI.
Clinical follow-up consisted of physical examinations, vaginal
cytology, tumor markers, and imaging studies. The patients’
detailed medical records, which included clinical and pathological
characteristics, treatment and outcome information, were retro-
spectively evaluated until the end of the follow-up period
(December 31, 2014).Missing 3 (0.3)
Histologic diagnosis
Adenocarcinoma 811 (71.6)
Adenosquamous 321 (28.4)
Depth of stromal invasion
50% 488 (43.1)
>50% 449 (39.7)
Missing 195 (17.2)
Grade of differentiation
1/2 810 (71.6)
3 194 (17.1)
Missing 128 (11.3)
Lymph-vascular space invasion
Positive 312 (27.6)
Negative 760 (67.1)
Missing 60 (5.3)
Tumor size
4 cm 870 (76.9)
>4 cm 167 (14.7)
Missing 95 (8.4)
Pelvic lymph node metastasis
Positive 210 (18.6)
Negative 895 (79.0)
Missing 27 (2.4)
Parametrial involvement
Positive 117 (10.4)
Negative 1009 (89.1)
Missing 6 (0.5)
Vaginal involvement
Positive 87 (7.7)
Negative 1043 (92.1)
Missing 2 (0.2)
Adjuvant treatment
No adjuvant 712 (62.9)
Chemotherapy alone 85 (7.5)
Radiotherapy alone 141 (12.5)
Chemoradiotherapy 194 (17.1)
FIGO International Federation of Gynecology and Obstetrics.2.3. Statistical analysis
Descriptive statistics were used to present patient characteris-
tics. For time-to-event data, recurrence-free survival (RFS) was
calculated as the period from primary surgical treatment to the
date of conﬁrmed recurrence or disease progression, or to the last
noted date of disease-free status on the medical records. Cancer-
speciﬁc survival (CSS) was calculated as the time of the initial
diagnosis of cervical AC/ASC until the date of disease-related death
or last follow-up. Disease-related death was deﬁned as death
caused by the malignancy or malignancy-associated complications.
Cases lost to follow-up and those alive at the end of the follow-up
period were considered censored observations. Survival curves
were generated using the Kaplan-Meier method and differences
between survival curves were compared using the log-rank test.
The univariate analysis was based on Cox regression, and the
stepwise multivariate Cox model using forward Wald method was
used to determine independent prognostic factors for survival.
Outcome predicting models were constructed using the signiﬁcant
covariates for either CSS or RFS. For prognostic score and risk group
classiﬁcation, Mann-Whitney test was used to compare scores be-
tween groups, and Goodness of ﬁt of classiﬁcation model evaluated
by chi-square test. Bootstrap resampling [14] was performed
randomly to construct new data sets (events per variable >10,
n ¼ 1132) followed by Cox regression analysis, which was repeated
1000 times, and the counts of selection as signiﬁcant were recorded
for each variable. Data were analyzed using SPSS software Version
20 (IBM SPSS Statistics 20; SPSS, Chicago, IL), and a p-value <0.05
was deﬁned as statistical signiﬁcance.3. Results
3.1. Patient’s characteristics
Between January 1, 1991 and December 31, 2011, a total of 1264
patients who received primary surgical treatment for stages I-II
cervical AC/ASC were retrieved from the tumor registries of the 17
TGOG member hospitals. Of these 1264 patients, 132 who didn’t
receive RH-PLND as a primary treatment were excluded from this
study. The remaining 1132 patients primarily treated with RH-
PLND were eligible for analysis.
The patient’s characteristics are shown in Table 1. The median
age of these 1132 patients was 46 years (range: 20e87 years). The
median follow-up of censored patients was 76.4 months (range:
0.5e272.4 months). Most (71.6%) of them were grade 1 or grade 2
differentiation and presented as FIGO stage I (86.9%). The mean
number of retrieved pelvic LN was 25.4 ± 12.8. Seven hundred and
twelve patients (62.9%) did not receive adjuvant treatment after
surgery, 141 (12.5%) received radiotherapy alone, 85 (7.5%)
chemotherapy alone, and 194 (17.1%) chemoradiotherapy. Positive
pelvic LN was found in 210 (18.6%) and PI in 117 (10.4%). Large tu-
mor size (>4 cm) was observed in 167 (14.7%), DSI (>50%) in 449
(39.7%), LVSI in 312 (27.6%), and vaginal involvement in 87 (7.7%).3.2. Analysis of prognostic factors
Univariate analyses by log rank test with 5-year CSS and RFS
rates are shown in Table S1. Univariate Cox regression for CSS and
RFS are shown in Tables 2 and 3. Histology subtype (ASC), FIGO
stage II, primary tumor size > 4 cm, DSI, LVSI, positive pelvic LN, PI,
and vaginal involvement showed signiﬁcant adverse effects on both
RFS and CSS. Young age (45 years old) had a signiﬁcant beneﬁcial
effect on RFS only.
Multivariate analyses by Cox regression for CSS and RFS are
shown in Tables 2 and 3. Three factors including positive pelvic LN
(RFS: p < 0.001; CSS: p < 0.001), PI (RFS: p ¼ 0.017; CSS: p < 0.001),
and DSI (RFS: p < 0.001; CSS: p ¼ 0.021) had signiﬁcant effects on
both RFS and CSS. FIGO stage II (p ¼ 0.024) and positive LVSI
(p ¼ 0.002) were signiﬁcant poor prognostic factors only for RFS.
3.3. Internal validation by bootstrap analyses
The ﬁve prognostic factors for CSS and/or RFS were taken into
consideration for the further internal validation. Using boot-
strapping by resampling 1000 times, it showed that the signiﬁcant
risk factors were the same as the original models for either CSS or
RFS except FIGO stage II (Table S2). The four factors DSI, LVSI,
Table 2
Univariate and multivariate cox regression analysis of factors associated with cancer-speciﬁc survival.
Univariate Stepwise multivariate (forward Wald method)
HR 95% CI p HR 95% CI p
Age (years)
45 Reference
>45 1.17 0.86e1.58 0.322
Histologic diagnosis
Adenocarcinoma Reference
Adenosquamous 1.49 1.09e2.03 0.012
FIGO stage
I Reference
II 2.86 2.03e4.04 <0.001
missing e
Tumour size
4 cm Reference
>4 cm 2.28 1.6e3.24 <0.001
Grade of differentiation
1/2 Reference
3 1.32 0.91e1.93 0.149
Depth of stromal invasion
50% Reference Reference
>50% 2.89 2.02e4.13 <0.001 1.65 1.08e2.53 0.021
Lymph-vascular space invasion
Negative Reference
Positive 3.70 2.72e5.03 <0.001
Pelvic lymph node metastasis
Negative Reference Reference
Positive 6.90 5.08e9.36 <0.001 4.43 2.97e6.61 <0.001
Parametrial involvement
Negative Reference Reference
Positive 5.73 4.14e7.94 <0.001 2.47 1.60e3.80 <0.001
Vaginal involvement
No Reference
Yes 2.21 1.43e3.4 <0.001
HR hazard ratio, CI conﬁdence interval.
Table 3
Univariate and multivariate cox regression analysis of factors associated with recurrence-free survival.
Univariate Stepwise multivariate (forward Wald method)
HR 95% CI p HR 95% CI p
Age (years)
45 Reference
>45 1.34 1.04e1.75 0.026
Histologic diagnosis
Adenocarcinoma Reference
Adenosquamous 1.31 1e1.72 0.048
FIGO stage
I Reference Reference
II 2.88 2.14e3.86 <0.001 1.53 1.06e2.2 0.024
Tumour size
4 cm Reference
>4 cm 2.20 1.63e2.96 <0.001
Grade of differentiation
1/2 Reference
3 1.14 0.82e1.59 0.439
Depth of stromal invasion
50% Reference Reference
>50% 3.65 2.67e4.99 <0.001 2.29 1.59e3.3 <0.001
Lymph-vascular space invasion
Negative Reference Reference
Positive 3.77 2.89e4.9 <0.001 1.69 1.2e2.37 0.002
Pelvic lymph node involvement
Negative Reference Reference
Positive 5.34 4.12e6.93 <0.001 2.77 1.96e3.91 <0.001
Parametrial involvement
Negative Reference Reference
Positive 4.61 3.45e6.17 <0.001 1.61 1.09e2.38 0.017
Vaginal involvement
No Reference
Yes 2.82 2e3.98 <0.001
HR hazard ratio, CI conﬁdence interval.
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classiﬁcation.
3.3.1. Prognostic score and risk group classiﬁcation
Outcome predicting models were constructed using the four
independent covariates for either CSS or RFS. The score was 0 for
depth of cervical stromal invasion <50% and 2 (approximate
average of 2.29 and 1.65) for stromal invasion S50%; 0 for LVSI-
negative and 1.5 (nearest approximate of 1.69) for LVSI-positive;
0 for negative pelvic node and 3.5 (approximate average of 2.77
and 4.43) for positive pelvic node; and 0 for no PI and 2 (approxi-
mate average of 2.47 and 1.61) for presence of PI. The probability of
cancer-speciﬁc death was signiﬁcantly higher in the high-risk
group (score S3.5, HR ¼ 6.0 95% CI 4.4e8.1), when compared
with the low-risk group (score 0e2, reference) (p < 0.001). The 5-
year CSS rates were 94.2% and 65.8% for the low-risk and high-
risk groups, respectively (Table 4). The probability of cancer
recurrencewas signiﬁcantly higher in the high-risk group (HR¼ 5.2
95% CI 4.0e6.7), when compared with the low-risk group
(p < 0.001). The 5-year RFS rates were 88.6% and 55.1%, for the low-
risk and high-risk groups respectively (Table 4).
3.4. Stratiﬁed analysis of survival based on risk group and adjuvant
therapy
The impact of adjuvant therapy on CSS and RFS according to
risk-groups was shown in Table 5. There were no signiﬁcant dif-
ferences on CSS or RFS of high- (Fig. S1) and low-risk groups
(Fig. S2) with or without adjuvant therapy. Among high-risk pa-
tients with pelvic LN metastasis had a signiﬁcant effect on RFS
(p ¼ 0.014) and CSS (p ¼ 0.016) (Fig. 1), while LN-negative high-risk
patients receiving adjuvant therapy (adjuvantþ) did not have bet-
ter RFS (p ¼ 0.176) and CSS (p ¼ 0.180) than those without adjuvant
therapy (adjuvante) (Fig. S3) for the higher mean risk score
(Table 5). The mean prognostic scores of adjuvantþ patients were
signiﬁcantly higher than adjuvant in both low-risk (1.4 versus 0.5,
p < 0.001) and high-risk group (5.7 versus 4.4, p < 0.001), and pelvic
LN-negative high-risk group (3.9 versus 3.6, p¼ 0.028), while pelvic
LN-positive patients did not differ in mean prognostic score
(p ¼ 0.293) (Table 5). Stratiﬁed by risk factors, adjuvantþ patients
tended to be associated with higher mean prognostic score, poorer
RFS and CSS as comparedwith adjuvante, with the exception of the
pelvic LN-positive group (Tables S3e6). Among those with LN-
positive, patients receiving chemoradiotherapy had marginally
better CSS than those receiving radiotherapy alone (5-year CSS
60.6% versus 48.2%, p ¼ 0.088) (Table S5), although the mean
prognostic score of the former was signiﬁcantly higher than the
latter (6.8 versus 6.2, p ¼ 0.018) (Tables S3 and S4).
4. Discussion
Most knowledge regarding the prognostic factors and effect of
adjuvant therapy following primary RH-PLND for early-stageTable 4
Hazard ratios of death and relapse according to prognostic score deﬁned risk groups.
Prognostica score No. of patients 5-Year CSS (%) HR for deat
Risk group
Low 0e2 803 94.2 1 (Referenc
High S3.5 329 65.8 6.0 (4.4e8.1
CSS cancer-speciﬁc survival, HR hazard ratio, CI conﬁdence interval, RFS recurrence-free
a Prognostic score: 0 for cervical stromal invasion <50%, negative lymphovascular sp
extension; 1.5 for positive LVSI; 2 for deep stromal invasion and positive parametrial ex
b Goodness of ﬁt of classiﬁcation model evaluated by chi-square test.cervical cancer comes from patients with SCC [4e9,15e18]. Most
published data regarding the prognostic factors and effect of
adjuvant therapy for cervical AC/ASC and other rare subtypes have
been based on small studies or single institutional studies
[11,18e22]. In this TGOG retrospective study (n ¼ 1132), PLN
metastasis, PI, DSI, and LVSI were independent prognostic factors
for cervical AC/ASC. Low- and high-risk groups were deﬁned by
prognostic scores derived from these four factors, and the 5-year
RFS and CSS were 88.6% and 94.2%, 55.1% and 65.8%, respectively
(RFS: p < 0.001; CSS; p < 0.001).
Lai et al. (n ¼ 456) found no differences in RFS and CSS between
the ASC and AC histology [21]. Baek et al. (n ¼ 337) observed no
differences in patterns of recurrence, time to recurrence, RFS, and
OS between AC and ASC [22]. A Korean multicenter retrospective
study (total n ¼ 1323; AC/ASC, n ¼ 255) reported that AC histology
was associated with poor survival outcomes than SCC, and prog-
nosis of ASC histology was closer to that of SCC histology [23].
Conversely, a meta-analysis reported that ASC may have poorer
outcomes compared with AC of the cervix [24]. Our study
demonstrated that ASC seemed slightly worse than AC in univariate
analysis, but they were not signiﬁcantly different on RFS and CSS in
multivariate analyses (Tables 2 and 3).
Age (>50) at diagnosis and FIGO stage were reported to be in-
dependent poor prognostic factors in cervical AC/ASC [21]. Baal-
bergen et al. reported that young age (<35) was a signiﬁcant good
prognostic factor [25]. In our study, age was not signiﬁcant for RFS
and CSS, but FIGO stage (p ¼ 0.024) had signiﬁcant effects on RFS
(Tables 2 and 3), but not selected for risk group classiﬁcation for
failed of internal validation (Table S2). Baek et al. reported that LVSI
and LN metastasis were signiﬁcantly associated with OS [22]. Kato
et al. concluded that LN metastasis, PI, and LVSI were independent
prognostic factors for cervical AC treated with surgery [26]. Park
et al. also reported that PI and LN metastasis were signiﬁcant fac-
tors for both RFS and OS in patients with early-stage cervical AC
after RH [27].
Yasuda et al. reported that low-risk group of stage IB ASC had a
good prognosis without postoperative adjuvant therapy [28]. In our
study, CSS and RFS were excellent in the low-risk group with or
without adjuvant therapy (Table 5). We conﬁrmed that adjuvant
therapy following RH-PLND for early-stage AC/ASC patients with
low prognostic score may not improve survival. Therefore, adjuvant
therapy could be omitted in order to decrease morbidity.
Cohn et al. also found that a trend of improved survival was
observed with the use of adjuvant therapy, speciﬁcally the use of
combined chemotherapy and radiotherapy after RH in AC patients
with LN metastasis [29]. A phase III randomized trial showed that
pelvic radiotherapy after RH-PLND prolonged progression-free
survival in women with LN-negative stage IB cervical cancer with
at least two high risk features (DSI, LVSI, or tumor diameter > 4 cm),
radiotherapy appears to be particularly beneﬁcial for patients with
AC/ASC [9]. In our study, impact of adjuvant therapy for LN-
negative high-risk group was non-signiﬁcant because of higher
prognostic scores of the adjuvantþ than adjuvant patientsh (95% CI) p 5-Year RFS (%) HR for relapse (95% CI) p
<0.001b <0.001a
e) 88.6 1 (Reference)
) <0.001 55.1 5.2 (4.0e6.7) <0.001
survival.
ace invasion (LVSI), negative pelvic lymph node (PLN), and negative parametrial
tension; 3.5 for positive PLN.
Table 5
Mean prognostic score distribution and survival stratiﬁed by adjuvant therapy and risk group.
Risk group Postoperative adjuvant therapy No. of patients Mean prognostic score 5-year CSS (%) 5-year RFS (%)
Low No adjuvant 654 (81%) 0.5 94.9 89.9
Adjuvant 149 (19%) 1.4 91.1 83.1
p <0.001a 0.248b 0.065b
High all No adjuvant 58 (18%) 4.4 74.3 63.9
Adjuvant 271 (82%) 5.7 64.1 53.3
p <0.001a 0.422b 0.423b
High PLNþ No adjuvant 19 (9%) 6.1 45.8 32.8
Adjuvant 191 (91%) 6.5 58.9 49.4
p 0.293a 0.016b 0.014b
High PLN No adjuvant 39 (33%) 3.6 87.1 79.3
Adjuvant 80 (67%) 3.9 76.8 62.1
p 0.028a 0.180b 0.176b
CSS cancer-speciﬁc survival, RFS recurrence-free survival, PLN pelvic lymph node.
a P-value based on Mann-Whitney test for mean risk score.
b P-value based on log-rank test for CSS and RFS.
Fig. 1. (A) Cancer-speciﬁc survival (p ¼ 0.016) and (B) recurrence-free survival (p ¼ 0.014) of pelvic node-positive high-risk patients with adjuvant versus without adjuvant therapy.
N.-F. Twu et al. / Surgical Oncology 25 (2016) 229e235234(Table 5), reﬂecting the importance of prospective study with
prognostic score stratiﬁcation.
Among high-risk patients with pelvic LN metastasis had a sig-
niﬁcant effect on RFS (p¼ 0.014) and CSS (p¼ 0.016). Besides, Those
with LN-positive and receiving chemoradiotherapy had marginally
better CSS than those receiving radiotherapy alone (p ¼ 0.088),
although the mean prognostic score of the former was signiﬁcantly
higher than the latter (p ¼ 0.018) (Table 5 and Tables S4eS5). Our
study suggests that adjuvant chemoradiotherapy might be the
choice for patients with pelvic LN metastasis. A randomized phase
III trial has shown improved survival for the treatment of advanced
cervical cancer adding weekly concurrent gemcitabine and two
cycles of adjuvant gemcitabine and cisplatin to standard single-
agent concurrent chemoradiotherapy (CCRT) [30]. Besides, a
phase III trial on bevacizumab has signiﬁcantly improved OS in
advanced and recurrent cervical cancer [31]. Pazopanib has sig-
niﬁcant improvements in PFS in a phase II randomized trial [32].
The 5-year CSS of LN-positive patients receiving chemo-
radiotherapy in this series was 60.6% (Table S4), further improve-
ment would lies in novel adjuvant combination chemotherapy
incorporating target therapeutic agents during and post-CCRT.
The strength of this study is that it includes the largest series of
patients with early-stage cervical AC/ASC and offers signiﬁcant
information regarding prognostic factors and adjuvant therapyafter RH-PLND. The major limitation of this study is its retrospec-
tive nature. The details of regimens and courses of chemotherapy/
chemoradiotherapy are lacking. To date, prospective researches
targeting cervical AC/ASC are limited. Despite the limitations, our
study suggests that adjuvant therapy has positive impact on sur-
vival in stage I-II AC/ASC patients with LN metastasis after primary
RH-PLND. Impact of adjuvant therapy for LN-negative high-risk
group was non-signiﬁcant because of higher prognostic scores of
the adjuvantþ than adjuvant patients, reﬂecting the importance
of prognostic score stratiﬁcation in future prospective studies.Conﬂict of interest statement
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